(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 May 2019 (09.05.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/089641 A1

(51) International Patent Classification:
A61K 45/00 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2018/058277

(22) International Filing Date:
30 October 2018 (30.10.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/579,666 31 October 2017 (31.10.2017) US
62/580,364 01 November 2017 (01.11.2017) US

(71) Applicant: **EISAI R&D MANAGEMENT CO., LTD.** [JP/JP]; 6-10 Koishikawa, 4-Chome, Bunkyo-ku, Tokyo 112-8088 (JP).

(72) Inventors; and

(71) Applicants: **AIRD, Daniel** [US/US]; 18 Wescroft Road, Reading, Massachusetts 01867 (US). **CORSON, Laura** [US/US]; 447 Washington Street, #3, Brookline, Massachusetts 02446 (US). **ZHU, Ping** [CN/US]; 44 Coolidge Farm Road, Boxboro, Massachusetts 01719 (US). **WARMUTH, Markus** [US/US]; 119 Blake Street, Newton, Massachusetts 02460 (US). **BUONAMICI, Silvia** [IT/US]; 680 Tremont Street, Apt. 4, Boston, Massachusetts 02118 (US). **SMITH, Peter Gerard** [GB/US]; 173A Franklin Street, Arlington, Massachusetts 02474 (US). **FEKKES, Peter** [NL/US]; 13 Leonard Street, Waltham, Massachusetts 02451 (US).

(74) Agent: **MACALPINE, Jill K.**; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2019/089641 A1

(54) Title: COMBINATION COMPRISING AT LEAST ONE SPLICEOSOME MODULATOR AND AT LEAST ONE INHIBITOR CHOSEN FROM BCL2 INHIBITORS, BCL2/BCLXL INHIBITORS, AND BCLXL INHIBITORS AND METHODS OF USE

(57) Abstract: The present disclosure provides pharmaceutical combinations comprising at least one spliceosome modulator and at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors. Also provided are methods of treating cancer comprising administering a therapeutically effective amount of at least one spliceosome modulator and a therapeutically effective amount of at least one inhibitor chosen from BCL2, BCL2/BCLxL, and BCLxL inhibitors.